“4+7”集中带量采购政策下胰岛素使用情况研究

目的分析“4+7”集中带量采购政策对邳州市人民医院胰岛素使用的影响,为政策制定和完善提供参考。方法对该院“4+7”集采政策实施前后胰岛素的单价、使用数量、使用金额、用药频度(DDDs)、限定日费用(DDC)等数据进行回顾性分析。结果“4+7”集采政策实施后,中标胰岛素价格平均降幅为45.60%;胰岛素用量增长11.38%,用药金额下降37.24%,节省费用为2242346.48元。中标胰岛素的DDDs除门冬胰岛素30注射液略有下降外其他均增加,DDC均降低。结论“4+7”集采政策实施大幅降低了胰岛素的药品费用,切实减轻了患者负担,可不断推进,为优化政策提供参考。

4+7集中带量采购对某院口服降血糖药及调血脂他汀类药物使用情况分析

目的 分析4+7集中带量采购对某院口服降血糖药及调血脂他汀类药物使用情况.方法 该研究应用某院的信息系统,分析4+7集中带量采购政策实施后2020年1月-2021年12月的口服降血糖药及调血脂他汀类药物使用情况.计算口服降血糖药及调血脂他汀类药物价格降幅.结果 启用4+7集中带量采购后,格列美脲片、阿卡波糖片(50mg*30片)、阿卡波糖片(100mg*30片)、盐酸二甲双胍缓释片、盐酸二甲双胍片、格列齐特缓释片、格列吡嗪控释片价格降幅分别为76.34%、91.16%、89.88%、39.71%、86.82%、50.79%、51.45%;阿托伐他汀钙片(10mg*14片)、阿托伐他汀钙片(20mg*7片)、瑞舒伐他汀钙片、匹伐他汀钙片价格降幅分别为64.18%、90.10%、82.38%、92.84%.结论 启用4+7集中带量采购政策后,可降低口服降血糖药及调血脂他汀类药物价格,可减轻患者用药负担.

The effects of the National Drug Pooled Procurement(NDPP)pilot program in China

In 2018,the Chinese government identified four municipalities and seven sub-provincial cities for the implementation of the National Drug Pooled Procurement(NDPP)pilot program(the“4+7”policy).In the present study,we analyzed the effects of the“4+7”policy with data of 25 pilot drugs from the National Healthcare Security Administration(NHSA)from the aspects of drug price,volume,and expenditure.After the implementation of the policy,the average price of total and winning drugs was decreased by 54.47%and 73.82%,respectively,while the DDDc of non-winning drugs was decreased by only 1.54%,and the DDDc of uncertificated generic drugs was increased 83.18%.The DDDs indicating the volume of total and winning drugs was increased by 21.18%and 353.98%,respectively,and the DDDs of non-winning drugs was decreased by 61.35%.The costs of total and non-winning drugs were decreased by 44.83%and 61.94%,respectively,and the cost of winning drugs was increased by 18.87%.The“4+7”policy reduced the price and cost of pilot drugs and improved the affordability and accessibility of drugs.However,there were also problems with unexpected excessive price increases of uncertificated generic drugs and relatively high prices of non-winning products.Therefore,we highly suggested promoting the normalization and institutionalization of pooled drug procurement,enhancing the administrative capacity of local procurement platforms,and strengthening monitoring the price of non-winning,especially for the uncertificated generic drugs.